191 related articles for article (PubMed ID: 29799676)
1. Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
Shapiro GI; Kristeleit RS; Burris HA; LoRusso P; Patel MR; Drew Y; Giordano H; Maloney L; Watkins S; Goble S; Jaw-Tsai S; Xiao JJ
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):107-118. PubMed ID: 29799676
[TBL] [Abstract][Full Text] [Related]
2. PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
Wang DD; Li C; Sun W; Zhang S; Shalinsky DR; Kern KA; Curtin NJ; Sam WJ; Kirkpatrick TR; Plummer R
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):89-98. PubMed ID: 27128213
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.
Grechko N; Skarbova V; Tomaszewska-Kiecana M; Ramlau R; Centkowski P; Drew Y; Dziadziuszko R; Zemanova M; Beltman J; Nash E; Habeck J; Liao M; Xiao J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):259-270. PubMed ID: 33909097
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.
Xiao JJ; Nowak D; Ramlau R; Tomaszewska-Kiecana M; Wysocki PJ; Isaacson J; Beltman J; Nash E; Kaczanowski R; Arold G; Watkins S
Clin Transl Sci; 2019 Jan; 12(1):58-65. PubMed ID: 30427584
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Drew Y; Ledermann J; Hall G; Rea D; Glasspool R; Highley M; Jayson G; Sludden J; Murray J; Jamieson D; Halford S; Acton G; Backholer Z; Mangano R; Boddy A; Curtin N; Plummer R
Br J Cancer; 2016 Mar; 114(7):723-30. PubMed ID: 27002934
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of absorption, distribution, metabolism, and excretion of [
Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
[TBL] [Abstract][Full Text] [Related]
7. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
Plummer R; Swaisland H; Leunen K; van Herpen CM; Jerusalem G; De Grève J; Lolkema MP; Soetekouw P; Mau-Sørensen M; Nielsen D; Spicer J; Fielding A; So K; Bannister W; Molife LR
Cancer Chemother Pharmacol; 2015 Oct; 76(4):723-9. PubMed ID: 26242220
[TBL] [Abstract][Full Text] [Related]
8. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline
Kristeleit R; Shapiro GI; Burris HA; Oza AM; LoRusso P; Patel MR; Domchek SM; Balmaña J; Drew Y; Chen LM; Safra T; Montes A; Giordano H; Maloney L; Goble S; Isaacson J; Xiao J; Borrow J; Rolfe L; Shapira-Frommer R
Clin Cancer Res; 2017 Aug; 23(15):4095-4106. PubMed ID: 28264872
[No Abstract] [Full Text] [Related]
9. Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.
Green ML; Ma SC; Goble S; Giordano H; Maloney L; Simmons AD; Beltman J; Harding TC; Xiao JJ
Cancer Chemother Pharmacol; 2022 May; 89(5):671-682. PubMed ID: 35397664
[TBL] [Abstract][Full Text] [Related]
10. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.
Murray J; Thomas H; Berry P; Kyle S; Patterson M; Jones C; Los G; Hostomsky Z; Plummer ER; Boddy AV; Curtin NJ
Br J Cancer; 2014 Apr; 110(8):1977-84. PubMed ID: 24556618
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors.
Kuppens IE; Witteveen PO; Schot M; Schuessler VM; Daehling A; Beijnen JH; Voest EE; Schellens JH
Invest New Drugs; 2007 Jun; 25(3):227-35. PubMed ID: 17146730
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
Liao M; Beltman J; Giordano H; Harding TC; Maloney L; Simmons AD; Xiao JJ
Clin Pharmacokinet; 2022 Nov; 61(11):1477-1493. PubMed ID: 36107395
[TBL] [Abstract][Full Text] [Related]
13. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
14. Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Lorusso D; Maltese G; Sabatucci I; Cresta S; Matteo C; Ceruti T; D'Incalci M; Zucchetti M; Raspagliesi F; Sonetto C; Sinno V; Ronzulli D; Giolitto S; de Braud F
Target Oncol; 2021 Jan; 16(1):59-68. PubMed ID: 33369704
[TBL] [Abstract][Full Text] [Related]
15. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
16. A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
Liao M; Jeziorski KG; Tomaszewska-Kiecana M; Láng I; Jasiówka M; Skarbová V; Centkowski P; Ramlau R; Górnaś M; Lee J; Edwards S; Habeck J; Nash E; Grechko N; Xiao JJ
Cancer Chemother Pharmacol; 2021 Nov; 88(5):887-897. PubMed ID: 34370076
[TBL] [Abstract][Full Text] [Related]
17. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
Moore K; Zhang ZY; Agarwal S; Burris H; Patel MR; Kansra V
Cancer Chemother Pharmacol; 2018 Mar; 81(3):497-503. PubMed ID: 29322231
[TBL] [Abstract][Full Text] [Related]
18. Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors.
Rolfo C; Swaisland H; Leunen K; Rutten A; Soetekouw P; Slater S; Verheul HM; Fielding A; So K; Bannister W; Dean E
Adv Ther; 2015 Jun; 32(6):510-22. PubMed ID: 26048134
[TBL] [Abstract][Full Text] [Related]
19. Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Konecny GE; Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; Ray-Coquard I; Aghajanian C; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Castro C; Green M; Simmons AD; Beltman J; Harding T; Lin KK; Goble S; Maloney L; Kristeleit RS; McNeish IA; Swisher EM; Xiao JJ
Gynecol Oncol; 2021 Jun; 161(3):668-675. PubMed ID: 33752918
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects.
Chen JJ; Hewitt LA
Drugs R D; 2018 Mar; 18(1):77-86. PubMed ID: 29392574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
